Table 1 The baseline characteristics of each study
From: The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
Study (Year) | Design | Sample size | Gender | Mean age (years) | N(%) HBeAg + | Liver Cirrhosis | N(%)HBVDNA detectable | NAs therapy-naive(%) | Follow-up time(m) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TDF | ETV | Male | Female | TDF | ETV | TDF | ETV | TDF | ETV | TDF | ETV | ||||
Koklu (2013) [14] | Retrospective cohort | 72 | 77 | 114 | 35 | 54.2 ± 10.5 | 52.4 ± 11.2 | 26 (17.4) | 72 | 77 | 136 (93.2) | NA | NA | 21.4 ± 10.02 | 24.0 ± 13.18 |
Goyal (2015) [15] | Retrospective cohort | 220 | 180 | 280 | 120 | 47.3 (24–65) | 48.1 (26–65) | 155 (38.7) | 220 | 180 | 400 (100) | 78.6 | 76.1 | 36 (11–60) | 45 (12–68) |
Choi (2017) [16] | Retrospective cohort | 557 | 557 | NA | NA | NA | NA | NA | 557 | 557 | NA | 100 | 100 | Up to 42 | |
Tsai (2017) [17] | Retrospective cohort | 83 | 359 | 322 | 120 | 54.9 ± 10.9a | 57.8 ± 10.8a | 103 (23.3) | 83 | 359 | 442 (100) | 100 | 100 | 20.3 ± 6.4 | 43.8 ± 18.2 |
Kim.B.G (2018) [19] | Retrospective cohort | 354 | 354 | 442 | 266 | 51 ± 11 | 51 ± 11 | 455 (64.3) | 156 | 169 | 708 (100) | 100 | 100 | 33 (21–46) | 66 (36–88) |
Kim.Y.M (2018) [18] | Retrospective cohort | 112 | 191 | 186 | 117 | 49.3 ± 10.9 | 47.7 ± 12.3 | 178 (58.8) | NA | NA | 303 (100) | 62.5 | 86.4 | 38.5 ± 9.2 | 66.6 ± 26.8 |
Yu (2018) [20] | Retrospective cohort | 176 | 406 | 376 | 206 | 49 (20–84)a | 53 (18–84)a | 316 (54.3) | 77 | 148 | 99 (17.9) | 100 | 100 | 33.6 (6.3–60.5) | 69.9 (6–119.4) |